Testing of Hematopoietic Neoplasms
Featured Topic Archive
- Communiqué: Newly Diagnosed Multiple Myeloma: Cytogenetic Classification
- Hot Topic: Middleware and the Clinical Hematology Laboratory
- Mayo Clinic Video: Polycythemia Vera (PV)
- Mayo Clinic Video: Myelofibrosis Update
- Mayo Clinic Video: Myelofibrosis
- Algorithm: Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
- Hot Topic: Classic Myeloproliferative Neoplasms
updated April 2012
What are Hematopoietic Neoplasms?
Hematopoietic neoplasms are clonal disorders of hematopoietic cells, which constitute red cells, white cells, and platelets. They typically manifest as leukemias, lymphomas, and plasma cell disorders. Leukemias predominantly involve peripheral blood and bone marrow, while lymphomas involve tissue-based sites such as lymph nodes, stomach, or skin.
Challenges in the Accurate Diagnosis of Hematopoietic Neoplasms
As technologies have advanced beyond typical chromosome analysis to include FISH- and PCR-based testing, accurate and cost-effective diagnosis of hematopoietic neoplasms has become much more challenging for clinicians and pathologists.
To address these challenges, Mayo Clinic clinicians and pathologists work together to establish unique test guidelines, algorithms, and specimen submission options that best utilize these technologies to provide the right diagnosis for the right patient.
Featured Hot Topic
The Classic Myeloproliferative Neoplasms: Optimizing Laboratory Testing for Hematologic Disorders
Curtis A. Hanson, MD, addresses guidelines for appropriate laboratory test utilization in hematologic disorders that represent the combined effort of the Divisions of Hematopathology and Laboratory Genetics.
These featured algorithms discuss diagnostic testing for myeloproliferative neoplasms:
- Myeloproliferative Neoplasm:
A Diagnostic Approach to
Peripheral Blood Evaluation
- Myeloproliferative Neoplasm: A Diagnostic Approach to
Bone Marrow Evaluation
Featured Disease Management Strategy
Molecular Evaluation of BCR/ABL1 in Chronic Myelogenous Leukemia (CML)
With multiple tests for this target available at Mayo Clinic, each designed for a specific need, it can be confusing which to order and when.
This Disease Management Strategies presentation discusses each of the currently available tests and how they are best used together for clinical management of CML patients.
- Hematopathology Consultation (Test ID: 5434)
- Leukemia/Lymphoma Immunophenotyping by Flow Cytometry (Test ID: LCMS)
- Hematologic Disorders, Leukemia/Lymphoma; Flow Hold Varies (Test ID: HLLFH)
- Chromosome Analysis, Hematologic Disorders, Bone Marrow (Test ID: BM)
- BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay (Test ID: BADX)
- BCR/ABL, Translocation 9;22, FISH (D-FISH) (Test ID: MCBR)
- Erythropoietin (EPO), Serum (Test ID: EPO)
- JAK2 V617F Mutation Detection: Blood (Test ID: JAK2B) | Bone Marrow (Test ID: JAK2M)
- JAK2 Exon 12 and Other Non-V617F Mutation Detection: Blood (Test ID: JAKXB) | Bone Marrow (Test ID: JAKXM)
- MPL Exon 10 Mutation Detection: Blood (Test ID: MPLB) | Bone Marrow (Test ID: MPLM)